Stoke Therapeutics (NASDAQ: STOK) insider transactions

In the twelve months to 10 November 2026, executives and directors of Stoke Therapeutics reported 81 open-market sales of 281,817 shares ($9.0m) and 0 open-market purchases, by 8 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Stoke Therapeutics shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
2 November 2026	Ticho Barry	Chief Medical Officer	Open-market sale, 10b5-1 plan	−6,995	$26.38	12,064	Form 4
2 November 2026	Ticho Barry	Chief Medical Officer	Open-market sale, 10b5-1 plan	−200	$26.99	11,864	Form 4
2 October 2026	Allan Jonathan	General Counsel & Corp Sec	Open-market sale, 10b5-1 plan	−627	$26.33	20,598	Form 4
1 October 2026	Ticho Barry	Chief Medical Officer	Open-market sale, 10b5-1 plan	−1,051	$26.16	19,059	Form 4
1 September 2026	Ticho Barry	Chief Medical Officer	Open-market sale, 10b5-1 plan	−3,945	$30.51	21,710	Form 4
1 September 2026	Ticho Barry	Chief Medical Officer	Open-market sale, 10b5-1 plan	−1,600	$31.06	20,110	Form 4
18 August 2026	Kaye Edward M. MD	Director	Open-market sale	−11,930	$32.01	125,194	Form 4
18 August 2026	Kaye Edward M. MD	Director	Open-market sale	−637	$32.47	124,557	Form 4
18 August 2026	Ticho Barry	Chief Medical Officer	Open-market sale	−4,525	$32.01	25,897	Form 4
18 August 2026	Ticho Barry	Chief Medical Officer	Open-market sale	−242	$32.47	25,655	Form 4
18 August 2026	Allan Jonathan	General Counsel & Corp Sec	Open-market sale	−2,716	$32.01	21,370	Form 4
18 August 2026	Allan Jonathan	General Counsel & Corp Sec	Open-market sale	−145	$32.47	21,225	Form 4
14 August 2026	Kaye Edward M. MD	Director	Option exercise	+26,250	—	137,124	Form 4
14 August 2026	Ticho Barry	Chief Medical Officer	Option exercise	+10,000	—	30,422	Form 4
14 August 2026	Allan Jonathan	General Counsel & Corp Sec	Option exercise	+6,000	—	24,086	Form 4
3 August 2026	Ticho Barry	Chief Medical Officer	Open-market sale, 10b5-1 plan	−5,907	$28.95	21,691	Form 4
3 August 2026	Ticho Barry	Chief Medical Officer	Open-market sale, 10b5-1 plan	−1,269	$29.45	20,422	Form 4
1 July 2026	Ticho Barry	Chief Medical Officer	Open-market sale, 10b5-1 plan	−6,728	$32.62	28,098	Form 4
1 July 2026	Ticho Barry	Chief Medical Officer	Open-market sale, 10b5-1 plan	−500	$33.27	27,598	Form 4
16 June 2026	Allan Jonathan	General Counsel & Corp Sec	Open-market sale, 10b5-1 plan	−1,457	$29.95	18,086	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Stoke Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.